Pulmonx Shareholders Back Board, Auditor and Pay Program
I'm LongbridgeAI, I can summarize articles.Pulmonx shareholders approved the board, auditor BDO USA, and executive compensation at its June 4, 2026 meeting. While analysts rate the stock a Buy with a $5 target, TipRanks' AI suggests Neutral due to weak financials like revenue softness and losses, despite positive technical signals and margin improvements.
Pulmonx ( (LUNG) ) has provided an update.
On June 4, 2026, Pulmonx Corporation held its 2026 Annual Meeting of Stockholders, with approximately 77% of eligible shares represented, and shareholders elected three Class III directors to serve until the 2029 annual meeting. Investors also ratified the appointment of BDO USA, P.C. as independent auditor for the 2026 fiscal year and approved, on an advisory basis, the company’s executive compensation program, signaling continued support for current governance and leadership structures.
These outcomes reinforce Pulmonx’s board composition and oversight framework for the next several years while confirming shareholder backing for its financial reporting and pay practices. The strong participation and approval levels may provide management with a stable governance platform as it pursues its strategic priorities in the medical technology market and maintains investor confidence in its corporate stewardship.
The most recent analyst rating on (LUNG) stock is a Buy
with a $5.00 price target.
To see the full list of analyst forecasts on Pulmonx stock,
see the LUNG Stock Forecast page.
Spark’s Take on LUNG Stock
According to Spark, TipRanks’ AI Analyst, LUNG is a Neutral.
The score is held back primarily by weak financial fundamentals—revenue softness, sizable ongoing losses, negative free cash flow, and higher leverage. Offsetting factors include constructive technical trend signals and an earnings call that pointed to improving margins, lower expense run-rate, strengthened liquidity, and a guided return to growth in H2, though execution and timing risks remain.
To see Spark’s full report on LUNG stock,
click here.
More about Pulmonx
Pulmonx Corporation operates in the medical technology sector, focusing on minimally invasive treatments for lung diseases such as severe emphysema. The company’s products target patients with advanced pulmonary conditions and are used by interventional pulmonologists and thoracic surgeons in hospital and specialty care settings.
Average Trading Volume: 547,774
Technical Sentiment Signal: Sell
Current Market Cap: $68M
For a thorough assessment of LUNG stock, go to TipRanks’ Stock Analysis page.